Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual lowdose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12months of treatment (-0.12mm[SD = 1.55 mm] and +0.30mm[SD= 2.54 mm], respectively; 2-sided P=.33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.
Low-dose aspirin in high-risk individuals with screen-detected subsolid lung nodules: A randomized phase II trial / Bonanni, B.; Serrano, D.; Maisonneuve, P.; Veronesi, G.; Johansson, H.; Aristarco, V.; Varricchio, C.; Cazzaniga, M.; Lazzeroni, M.; Rampinelli, C.; Bellomi, M.; Vecchi, M.; Spaggiari, L.; Vornik, L.; Brown, P. H.; Beavers, T.; Guerrieri-Gonzaga, A.; Szabo, E.. - In: JNCI CANCER SPECTRUM. - ISSN 2515-5091. - 4:6(2021), p. pkaa096. [10.1093/JNCICS/PKAA096]
Low-dose aspirin in high-risk individuals with screen-detected subsolid lung nodules: A randomized phase II trial
Veronesi G.;
2021-01-01
Abstract
Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb trial (NCT02169271) to study the efficacy of low-dose aspirin to reduce the size of subsolid lung nodules (SSNs). A total of 98 current or former smokers (67.3% current) undergoing annual lowdose computed tomography screening with persistent SSNs were randomly assigned to receive aspirin 100 mg/day or placebo for 1 year. There was no difference in change in the sum of the longest diameters of target nodules in the placebo and aspirin arm after 12months of treatment (-0.12mm[SD = 1.55 mm] and +0.30mm[SD= 2.54 mm], respectively; 2-sided P=.33 primary endpoint). There were no changes observed in subgroup analyses by individual characteristics or nodule type. One year of low-dose aspirin did not show any effect on lung SSNs. SSNs regression may not be the proper target for aspirin, and/or longer duration may be needed to see SSNs modifications.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
